Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab Onset of Effect in Severe Eosinophilic Asthma
NCT02869438Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2016
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of benralizumab in asthma, sponsored by AstraZeneca. Started Nov 2016; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02869438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869438.